NGGT002
/ NGGT (Suzhou) Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
November 14, 2024
Safety and Efficacy Study of NGGT002 in cPKU Adult Subjects
(clinicaltrials.gov)
- P1/2 | N=18 | Recruiting | Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd.
New P1/2 trial • Metabolic Disorders • Phenylketonuria • Rare Diseases
October 02, 2024
AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
(clinicaltrials.gov)
- P1/2 | N=12 | Recruiting | Sponsor: NGGT INC. | Not yet recruiting ➔ Recruiting
Enrollment open • Gene Therapies • Metabolic Disorders • Phenylketonuria • Rare Diseases
June 17, 2024
AAV Gene Therapy Clinical Study in Adult Classic PKU
(clinicaltrials.gov)
- P1/2 | N=12 | Not yet recruiting | Sponsor: NGGT INC. | Initiation date: May 2024 ➔ Nov 2024
Gene therapy • Trial initiation date • Gene Therapies • Metabolic Disorders • Phenylketonuria • Rare Diseases
April 02, 2024
Safety and Efficacy of NGGT002 (rAAV8-hPAH) in Adults with Phenylketonuria (PKU): Results from an Investigator Initiated Study
(ASGCT 2024)
- P1 | "A single infusion of NGGT002 gene therapy is well tolerated in adults with PKU. Encouraging evidence of significant and stable efficacy has been observed. These results support further clinical development of NGGT002."
Clinical • Gene Therapies • Genetic Disorders • Hepatology • Liver Failure • Metabolic Disorders • Phenylketonuria • Psychiatry • Rare Diseases
March 27, 2024
AAV Gene Therapy Clinical Study in Adult Classic PKU
(clinicaltrials.gov)
- P1/2 | N=12 | Not yet recruiting | Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd.
Gene therapy • New P1/2 trial • Gene Therapies • Metabolic Disorders • Phenylketonuria • Rare Diseases
September 29, 2023
AAV8 Gene Therapy in PKU Adult Subjects
(clinicaltrials.gov)
- P1 | N=9 | Recruiting | Sponsor: First Affiliated Hospital Bengbu Medical College
Gene therapy • New P1 trial • Gene Therapies • Metabolic Disorders • Phenylketonuria • Rare Diseases
1 to 6
Of
6
Go to page
1